Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC4703 Phase 1 Safety and PK/PD Study
NCT05552274Phase 1Completed
- Sponsor
- Eccogene
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ECC4703 in Nonalcoholic steatohepatitis (NASH) and dyslipidemia (4 arms), sponsored by Eccogene. Primary endpoint: Number of participants with adverse events. Started Aug 2022; status: completed.
02
Drugs
ECC4703
03
Conditions
Nonalcoholic steatohepatitis (NASH)dyslipidemia
Beyond the preview
Go deeper on NCT05552274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552274.